Emily Beman is a counsel in the firm’s Life Sciences Group. She joined Goodwin in 2010.





A selection of Ms. Beman’s recent representative matters is below.

  • Advanced Medical Solutions in its acquisition of Sealantis Limited
  • bluebird bio in its strategic collaboration with TC BioPharm
  • bluebird bio in its strategic collaboration with Regeneron
  • BridgeBio Pharma, Inc. subsidiary QED Therapeutics in its $2.45 billion strategic collaboration with Helsinn
  • BridgeBio Pharma, Inc. in its joint venture with Maze Therapeutics to advance precision medicine to treat cardiovascular disease.
  • BridgeBio Pharma, Inc. subsidiary Eidos Therapeutics in connection with a licensing agreement that grants Alexion an exclusive license to develop and commercialize AG10 in Japan
  • BridgeBio Pharma, Inc. in its launch of its subsidiary, QED Therapeutics, including its in-license of infigratinib from Novartis
  • C4 Therapeutics in its strategic collaboration with Roche to develop degrader-based medicines
  • C4 Therapeutics in its strategic collaboration with Calico Life Sciences
  • Cephalon in its exclusive license agreement with Eagle Pharmaceuticals with a total deal value in excess of $120 million, plus royalties
  • CRISPR Therapeutics in its collaboration with Vertex Pharmaceuticals, valued up to $2.6 billion with $105 million upfront
  • CRISPR Therapeutics in its collaboration with ViaCyte, focused on stem cell therapies for the treatment of diabetes
  • CRISPR Therapeutics in its collaboration with Bayer, valued up to $635 million with $335 million upfront
  • CRISPR Therapeutics in its strategic in-licensing and collaboration agreement with Anagenesis Biotechnologies
  • Enara Bio in its strategic collaboration and license agreement with Boehringer Ingelheim to discover novel shared antigens for cancer immunotherapies
  • Enterome in its collaboration with Takeda
  • F-star Alpha in its exclusive purchase option agreement with Bristol-Myers Squibb with potential deal value up to $475 million
  • Gadeta in its strategic collaboration with Kite (a Gilead company) to develop novel gamma delta TCR therapies for the treatment of various cancers, by way of an option-to-acquire structure
  • Lacerta in its research, collaboration and licensing agreement with UCB Biopharma SRL (“UCB”) pursuant to which the parties will collaborate on developing novel gene therapies focused on a central nervous system disease with a high unmet need
  • Naurex in its $560 million sale to Allergan
  • Staten Biotechnology in its collaboration with Novo Nordisk to develop novel treatments for dyslipidaemia
  • Teva Pharmaceuticals, in its sale of its specialty global women’s health business for a combined value of $2.5 billion, including sale of Paragard®  business to CooperSurgical for $1.1 billion, ex-U.S. women’s health business to CVC Capital Partners for $703 million, and Plan B One-Step® franchise to Foundation Consumer Healthcare for $675 million
  • Teva Pharmaceuticals, in its $40.5 billion acquisition of Allergan’s (fka Actavis/Watson) Global Generic Pharmaceuticals Business
  • Teva Pharmaceuticals, in connection with its sale of oncology assets to Ignyta
  • Teva Pharmaceuticals, in connection with patent license and settlement agreements related to settlements of various brand and generic pharmaceutical patent litigation matters
  • Licensing of intellectual property assets from research institutions
Professional Experience

Ms. Beman has undertaken a client secondment at bluebird bio.

Prior to joining Goodwin, Ms. Beman was a Special Assistant District Attorney in the Kings County District Attorney’s Office.


While in law school, Ms. Beman was the Alumni Affairs Editor of the Connecticut Law Review.

In The News









J.D., 2009
University of Connecticut School of Law


B.S., Chemistry, 2006
Trinity College



New York
U.S. Patent and Trademark Office (USPTO)
Profile Image
Get In Touch
Our clients rely on us for world-class advisory services, counsel on complex transactional work and high-stakes litigation. Specializing in matters involving the financial, life sciences, private equity, real estate, and technology industries, we use a collaborative, cross-disciplinary approach to resolve our clients’ most challenging issues. To find out more, please contact us.


Nos équipes interviennent aux côtés de nos clients, industriels, fonds d’investissement, startups, institutions financières et dirigeants, dans le cadre de transactions et de contentieux complexes, et apportent des conseils de tout premier plan dans les secteurs financiers, des Sciences de la Vie, du Private Equity, de l’immobilier et des technologies. Nous traitons les dossiers juridiques de manière intègre, ingénieuse, souple et audacieuse pour répondre efficacement aux enjeux propres à chacun de nos clients, quels que soient la taille de l’opération et le secteur d’activité. Pour en savoir plus, contactez-nous.

Unsere Kunden verlassen sich auf unsere erstklassige Beratung, vor allem im Hinblick auf komplexe Transaktionen und High-Stakes-Prozesse. Spezialisiert auf Angelegenheiten der Finanz-, Life-Sciences-, Private-Equity-, Immobilien-und Technologie-Branchen, verwenden wir einen kooperativen und interdisziplinären Ansatz, um Fragen unserer Kunden auch in extremen Spezialsituationen einer Lösung zuzuführen. Sie wollen mehr erfahren? Kontaktieren Sie uns gerne.

Search Other Lawyers
Recherche par Pratique